Rio Tinto (ADR) vs Recursion Pharmaceuticals Inc — how do they compare? Rio Tinto (ADR) trades at $102.5 (market cap $170.47B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B). The key difference: Rio Tinto (ADR) is far larger — about 91.7× Recursion Pharmaceuticals Inc's market cap, and Rio Tinto (ADR) pays a 4.48% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RIO | RXRX | |
|---|---|---|
Market Cap | $170.47B | $1.86B |
Sector | Industrials | Health |
52-Week High | $112.04 | $6.79 |
52-Week Low | $61.98 | $2.84 |
Enterprise Value | $183.82B | $1.38B |
Dividend Yield | 4.48% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Trailing returns across standard periods
Latest headlines on both assets
Rio Tinto is a global mining company that produces metals and minerals including iron ore, aluminium, copper, and lithium. Its operations supply materials used in construction, manufacturing, transportation, and energy systems.
Read more on RIO →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →